The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
Cyclodextrins as pharmaceutical solubilizers
Brewster, M. E., & Loftsson, T. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.012 · Cited by 1,882
Cyclodextrins and their pharmaceutical applications
LOFTSSON, T., & DUCHENE, D. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.044 · Cited by 1,764
Nanosuspensions in drug delivery
Rabinow, B. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1494 · Cited by 1,524
Dendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158
Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence
Smith, I. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.3.463-496.2003 · Cited by 1,154
Tomalia, D. A. (2005) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2005.01.007 · Cited by 1,115
Point-of-Care Diagnostics for Global Health
Yager, P., Domingo, G. J., & Gerdes, J. (2008) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.10.061807.160524 · Cited by 1,076
Nanosizing — Oral formulation development and biopharmaceutical evaluation
Kesisoglou, F., Panmai, S., & Wu, Y. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.003 · Cited by 1,055
Lindenberg, M., Kopp, S., & Dressman, J. B. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.001 · Cited by 864
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 745
The influence of surface modification on the cytotoxicity of PAMAM dendrimers
Jevprasesphant, R. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00623-3 · Cited by 726
Global epidemiology of tuberculosis
Dye, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68384-0 · Cited by 716
Treatment for tuberculosis, guidelines for national programmes
Gyselen, E. A. (1994) · Health Policy · doi:10.1016/0168-8510(94)90025-6 · Cited by 708
Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J., & Dye, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14333-4 · Cited by 689
Polymeric Micelles for Drug Delivery
Croy, S., & Kwon, G. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206779026245 · Cited by 603
DEMANUELE, A., & ATTWOOD, D. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.012 · Cited by 571
Chiappetta, D. A., & Sosnik, A. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.03.022 · Cited by 567
Self-citationBrannon-Peppas, L. (1995) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)00324-x · Cited by 528
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregoriadis, G., Swain, C. P., Wills, E. J., & Tavill, A. S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90682-5 · Cited by 401
Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 388
Hiscock, C., & ISDALE, I. C. (1964) · PubMed · Cited by 370
Programmes and principles in treatment of multidrug-resistant tuberculosis
Mukherjee, J. S., Rich, M. L., Socci, A. R., Joseph, J. K., Virú, F. A., Shin, S. S., Furin, J. J., Becerra, M. C., Barry, D. J., Kim, J. Y., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15496-2 · Cited by 333
Solid State Amorphization of Pharmaceuticals
Willart, J. F., & Descamps, M. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800092t · Cited by 332
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314
Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C., & Orme, I. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2294-2301.2005 · Cited by 306
Mannose-targeted systems for the delivery of therapeutics
Irache, J. M., Salman, H. H., Gamazo, C., & Espuelas, S. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.6.703 · Cited by 293
Sham, J. O.-H., Zhang, Y., Finlay, W. H., Roa, W. H., & Löbenberg, R. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.041 · Cited by 284
Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis
Kaufmann, S. H. E., & McMichael, A. J. (2005) · Nature Medicine · doi:10.1038/nm1221 · Cited by 273
Oral solid lipid nanoparticle-based antitubercular chemotherapy
Pandey, R., Sharma, S., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2005.08.009 · Cited by 271
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages
Vyas, S. P., Kannan, M. E., Jain, S., Mishra, V, & Singh, P. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.08.017 · Cited by 262
Moghimi, S. M., Muir, I. S., Illum, L., Davis, S. S., & Kolb-Bachofen, V (1993) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(93)90137-e · Cited by 259
Nanomedicine for respiratory diseases
Pison, U., Welte, T., Giersig, M., & Groneberg, D. A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.068 · Cited by 255
Sharma, A., Sharma, S., & Khuller, G. K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh411 · Cited by 251
Role of Nanotechnology in Pharmaceutical Product Development
Devalapally, H., Chakilam, A., & Amiji, M. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20875 · Cited by 230
Advances in lipid nanodispersions for parenteral drug delivery and targeting
Constantinides, P. P., Chaubal, M. V., & Shorr, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.013 · Cited by 230
Peters, K. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.77 · Cited by 228
Pandey, R., Zahoor, A., Sharma, S., & Khuller, G. K. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.07.001 · Cited by 220
Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine
Singh, K. K., & Vingkar, S. K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.035 · Cited by 215
Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers
Kumar, P. V., Asthana, A., Dutta, T., & Jain, N. K. (2006) · Journal of Drug Targeting · doi:10.1080/10611860600825159 · Cited by 215
Tuberculosis chemotherapy: current drug delivery approaches
du Toit, L. C., Pillay, V., & Danckwerts, M. P. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-118 · Cited by 212
Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.1.0010 · Cited by 190
Antitubercular inhaled therapy: opportunities, progress and challenges
Pandey, R., & Khuller, G. K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki027 · Cited by 188
Nanomaterials and Nanosystems for Biomedical Applications
(2007) · Springer eBooks · doi:10.1007/978-1-4020-6289-6 · Cited by 181
Ohashi, K., Kabasawa, T., Ozeki, T., & Okada, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.027 · Cited by 178
THE PATHOGENESIS OF TUBERCULOSIS
Rook, G. A. W., & Hernandez-Pando, R. (1996) · Annual Review of Microbiology · doi:10.1146/annurev.micro.50.1.259 · Cited by 178
The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.
Blomberg, B., Spinaci, S., Fourie, B. P., & Laing, R. O. (2001) · Europe PMC (PubMed Central) · Cited by 176
Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.011 · Cited by 164
Deol, P., & Khuller, G. K. (1997) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(96)00088-8 · Cited by 160
Wijagkanalan, W., Kawakami, S., Takenaga, M., Igarashi, R., Yamashita, F., & Hashida, M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.10.011 · Cited by 158
Upregulated Genes In Sporadic, Idiopathic Pulmonary Arterial Hypertension
Edgar, A. J., Chacón, M. R., Bishop, A. E., Yacoub, M. H., & Polak, J. M. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-1 · Cited by 157
Polymeric Particulates to Improve Oral Bioavailability of Peptide Drugs
Delié, F., & Blanco‐Prieto, M. J. (2005) · Molecules · doi:10.3390/10010065 · Cited by 150
Kisich, K. O., Gelperina, S. E., Higgins, M. P., WILSON, S., Шипуло, Е. В., OGANESYAN, E., & Heifets, L. B. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.05.062 · Cited by 145
Oh, Y., Nix, D. E., & Straubinger, R. M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.2104 · Cited by 143
New anti-tuberculosis drugs in clinical trials with novel mechanisms of action
Rivers, E. C., & Mancera, R. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.004 · Cited by 141
Responding to Market Failures in Tuberculosis Control
Gupta, R., Kim, J. Y., Espinal, M., Caudron, J.-M., Pécoul, B., Farmer, P. E., & Raviglione, M. C. (2001) · Science · doi:10.1126/science.1061861 · Cited by 136
Ahmad, Z., PANDEY, R., Sharma, S., & Khuller, G. K. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.12.009 · Cited by 129
Deol, P., Khuller, G. K., & Joshi, K. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1211 · Cited by 128
Enantiomeric PLA–PEG block copolymers and their stereocomplex micelles used as rifampin delivery
Chen, L., Xie, Z., Hu, J., Chen, X., & Jing, X. (2006) · Journal of Nanoparticle Research · doi:10.1007/s11051-006-9103-8 · Cited by 127
Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice
Klemens, S. P., Cynamon, M. H., Swenson, C. E., & Ginsberg, R. S. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.967 · Cited by 120
Gill, S., Löbenberg, R., Ku, T., Azarmi, S., Roa, W., & Prenner, E. J. (2007) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2007.015 · Cited by 118
Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model
Pandey, R., & Khuller, G. K. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl128 · Cited by 118
Formulation of rifampicin–cyclodextrin complexes for lung nebulization
Tewes, F., Brillault, J., Couet, W. R., & Olivier, J. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.007 · Cited by 110
Gaspar, M. M., Cruz, A., Penha, A. F., Reymão, J., de Sousa, A. C. C., Eleutério, C., Domingues, H. S., Fraga, A. G., Longatto‐Filho, A., Cruz, M. E. M., et al. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.08.008 · Cited by 107
Preparation and characterization of niosomes containing rifampicin for lung targeting
Jain, C. P., & Vyas, S. P. (1995) · Journal of Microencapsulation · doi:10.3109/02652049509087252 · Cited by 102
Seki, J., Sonoke, S., Saheki, A., Fukui, H., Sasaki, H., & Mayumi, T. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.12.022 · Cited by 101
Treatment of tuberculosis: present status and future prospects.
Onyebujoh, P., Zumla, A. I., Ribeiro, I., Rustomjee, R., Mwaba, P., Gomes, M., & Grange, J. M. (2005) · Europe PMC (PubMed Central) · Cited by 97
In vitro toxicity and permeation of cyclodextrins in Calu-3 cells
Matilainen, L., Toropainen, T., Vihola, H., Hirvonen, J. J., Järvinen, T., Jarho, P., & Järvinen, K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.003 · Cited by 95
Niosomes as Nanocarrier Systems
Şahin, N. Ö. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6289-6_4 · Cited by 94
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model
Pandey, R. B. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh260 · Cited by 91
Anisimova, Y. V., Gelperina, S. I., Peloquin, C. A., & Heifets, L. B. (2000) · Journal of Nanoparticle Research · doi:10.1023/a:1010061013365 · Cited by 87
Mariappan, T. T., & Singh, S. (2003) · PubMed · Cited by 84
Stability of rifampicin in dissolution medium in presence of isoniazid
Shishoo, C. J., Shah, S. A., Rathod, I. S., et al. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00286-0 · Cited by 82
The Pathogenesis of Tuberculosis
Schluger, N. W. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.f293 · Cited by 80
Cyclodextrins as a potential carrier in drug nebulization
Évrard, B., Bertholet, P., Gueders, M. M., et al. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.010 · Cited by 79
Singh, S., Mariappan, T. T., Sharda, N., et al. (2000) · Pharmacy and Pharmacology Communications · doi:10.1211/146080800128736277 · Cited by 78
Kumar, P. V., Agashe, H. B., Dutta, T., & Jain, N. K. (2006) · Current Drug Delivery · doi:10.2174/156720107779314794 · Cited by 77
Jiang, Z., You, Y., Deng, X., & Hao, J. (2007) · Polymer · doi:10.1016/j.polymer.2007.06.003 · Cited by 72
Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis
El-Ridy, M. S., Mostafa, D. M., Shehab, A., Nasr, E. A. A., & El-Alim, S. H. A. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.09.017 · Cited by 71
Leitzke, S., Bucke, W., Börner, K., Müller, R. H., Hahn, H. H., & Ehlers, S. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.459 · Cited by 59
Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections
Gaspar, M. M., Cruz, A., Fraga, A. G., Castro, A. G., Cruz, M. E. M., & Pedrosa, J. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783955629 · Cited by 58
Characterization of a rat alveolar macrophage cell line that expresses a functional mannose receptor
Lane, K. B., Egan, B. S., Vick, S., Abdolrasulnia, R., & Shepherd, V. L. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.3.345 · Cited by 47
Düzgüneş, N., Flasher, D., Reddy, M. V., Luna‐Herrera, J., & Gangadharam, P. R. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.11.2618 · Cited by 45
Ellard, G. A., & Fourie, P. B. (1999) · PubMed · Cited by 42
WHO declares tuberculosis a global emergency
World Health Organization (1993) · Sozial- und Präventivmedizin · doi:10.1007/bf01624546 · Cited by 39
Epidemiology and Treatment of Multidrug Resistant Tuberculosis
Mitnick, C. D., Appleton, S. C., & Shin, S. S. (2008) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0028-1085702 · Cited by 38
Potential Tuberculostatic Agent: Micelle‐forming Pyrazinamide Prodrug
Silva, M., Ricelli, N. L., Seoud, O. A. E., Santilli, C. V., Ferreira, A. G., Sato, D. N., Leite, C. Q. F., & Ferreira, E. I. (2006) · Archiv der Pharmazie · doi:10.1002/ardp.200500039 · Cited by 37
Mullaicharam, A. R., & Murthy, R. S. R. (2004) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(04)50020-5 · Cited by 37
Lung surfactant as a drug delivery system
Vermehren, C., Frøkjær, S., AURSTAD, T., & HANSEN, J. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.029 · Cited by 35
Review: Managing TB in the 21st century: existing and novel drug therapies
Guy, E., & Mallampalli, A. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808099522 · Cited by 30
In vivo and in vitro uptake of surfactant lipids by alveolar type II cells and macrophages
Poelma, D. L. H., Zimmermann, L. J. I., Scholten, H. H., Lachmann, B., & van Iwaarden, J. F. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00478.2001 · Cited by 29
Ethical issues in research in low-income countries.
Benatar, S. R., & Fleischer, T. E. (2007) · PubMed · Cited by 28
Rifamycins. LIX. Acetyl migration in rifampicin
Maggi, N., Vigevani, A., Gallo, G. G., et al. (1968) · Journal of Medicinal Chemistry · doi:10.1021/jm00311a004 · Cited by 26
Positioning of Rifampicin in the Biopharmaceutics Classification System (BCS)
Mariappan, T. T., & Singh, S. (2006) · Clinical Research and Regulatory Affairs · doi:10.1080/10601330500533990 · Cited by 25
Preparation of Polymeric Micelles for use as Carriers of Tuberculostatic Drugs
Silva, M., FERREIRA, E. I., Leite, C. Q. F., & Sato, D. N. (2007) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v6i4.14665 · Cited by 25
Drug-resistant tuberculosis: controversies and challenges in pediatrics
Smith, K. C., & Seaworth, B. J. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.6.995 · Cited by 20
Formulation and Evaluation of a Salted-out Isoniazid-loaded Nanosystem
du Toit, L. C., Pillay, V., Choonara, Y. E., & Iyuke, S. E. (2008) · AAPS PharmSciTech · doi:10.1208/s12249-007-9016-6 · Cited by 20
Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate)
Шипуло, Е. В., Lyubimov, I. I., Максименко, О. О., Vanchugova, L. V., Oganesyan, E. A., Sveshnikov, P. G., Бикетов, С. Ф., Severin, E. S., Heifets, L. B., & Gelperina, S. E. (2008) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-008-0073-2 · Cited by 18
Mehta, S. K., Bhasin, K. K., Mehta, N., et al. (2004) · Colloid & Polymer Science · doi:10.1007/s00396-004-1181-5 · Cited by 15
Patents on therapeutics in developing countries: the challenges ahead
Bhalla, A., Suri, V., & Malhotra, S. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.8.1015 · Cited by 2
Cited by
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,864
Toxicology and clinical potential of nanoparticles
Yildirimer, L., Thanh, N. T. K., Loizidou, M., & Seifalian, A. M. (2011) · Nano Today · doi:10.1016/j.nantod.2011.10.001 · Cited by 676
Nanoparticles: Alternatives Against Drug-Resistant Pathogenic Microbes
Rudramurthy, G., Swamy, M., Sinniah, U., & Ghasemzadeh, A. (2016) · Molecules · doi:10.3390/molecules21070836 · Cited by 556
Cheng, Y., Zhao, L., Li, Y., & Xu, T. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00097c · Cited by 515
Biocompatibility and Toxicity of Nanoparticles and Nanotubes
Li, X., Wang, L., Fan, Y., Feng, Q., & Cui, F.-Z. (2012) · Journal of Nanomaterials · doi:10.1155/2012/548389 · Cited by 351
Metadata
- Authors
- Sosnik, A., Carcaboso, Á. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 62
- Issue
- 4-5
- Pages
- 547-559
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W1984699742
- Cited by
- 264
- References
- 105
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.